10q10k10q10k.net
SIGA TECHNOLOGIES INC

SIGA TECHNOLOGIES INCSIGAEarnings & Financial Report

Nasdaq

SIGA Technologies, Inc. is an American pharmaceutical company founded in 1995, based in New York City, which develops and sells pharmaceutical solutions for the antiviral treatment of smallpox, monkeypox, cowpox, and vaccinia complications.

SIGA Q3 2025 Key Financial Metrics

Revenue

$2.6M

Gross Profit

$1.6M

Operating Profit

$-10.2M

Net Profit

$-6.4M

Gross Margin

61.8%

Operating Margin

-390.2%

Net Margin

-243.0%

YoY Growth

-73.8%

EPS

$-0.09

Financial Flow

SIGA TECHNOLOGIES INC Q3 2025 Financial Summary

SIGA TECHNOLOGIES INC reported revenue of $2.6M for Q3 2025, with a net profit of $-6.4M (-243.0% margin). Cost of goods sold was $1.0M, operating expenses totaled $11.8M.

Key Financial Metrics

Total Revenue$2.6M
Net Profit$-6.4M
Gross Margin61.8%
Operating Margin-390.2%
Report PeriodQ3 2025

SIGA TECHNOLOGIES INC Annual Revenue by Year

SIGA TECHNOLOGIES INC annual revenue history includes year-by-year totals (for example, 2024 revenue was $138.7M).

YearAnnual Revenue
2024$138.7M
2023$139.9M
2022$110.8M

Income Statement

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Revenue$116.5M$25.4M$21.8M$10.0M$81.5M$7.0M$81.1M$2.6M
YoY Growth925.5%205.5%271.0%8.4%-30.1%-72.3%271.9%-73.8%

Balance Sheet

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Assets$254.4M$243.1M$192.7M$195.4M$244.3M$247.1M$235.3M$231.6M
Liabilities$57.5M$78.2M$25.1M$25.9M$28.5M$30.9M$26.0M$28.1M
Equity$196.9M$165.0M$167.6M$169.4M$215.8M$216.1M$209.3M$203.5M

Cash Flow

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Operating CF$79.0M$-6.1M$6.0M$-7.4M$56.3M$7.1M$63.1M$-9.8M